Full-Time
Innovation Lead
Halma
1,001-5,000 employees
Global safety, health, environmental technology company
Compensation Overview
£75k - £90k/yr
Wolverhampton, UK
Hybrid
Hybrid working with flexible arrangements.
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Halma
See people who can refer or advise you
- A degree in Engineering, Product, Innovation, Business, or equivalent experience gained through relevant roles.
- Demonstrated experience working in innovation, research and development, product development, or a technically led commercial environment.
- Strong understanding of structured innovation approaches, applied pragmatically in a business context.
- Commercial awareness, with the ability to assess viability, value and risk alongside technical feasibility.
- Confidence engaging with engineering and technical teams, with the ability to challenge and influence constructively.
- A proven ability to work cross-functionally and progress initiatives without formal authority.
- Strong analytical, problem-solving and decision-making capability in ambiguous environments.
- Lead the identification, development and prioritisation of innovation opportunities aligned to Fortress strategy and market needs.
- Own and manage the innovation pipeline, progressing concepts from early exploration through to validated handover into Product, Engineering or other delivery teams.
- Work closely with research and development, Engineering, Product Management and Safety Services to explore feasibility, risk and value of new ideas.
- Monitor industry trends, emerging technologies, competitor activity and customer insight to inform opportunity identification.
- Facilitate ideation sessions, workshops and structured problem-solving activities across the business.
- Engage with customers, partners and external bodies to validate concepts and understand emerging needs.
- Support licensing, partnership and acquisition-related innovation activity where appropriate.
- Explore adjacent-market and platform innovation, not just incremental product development.
- Translate emerging technology trends into practical, value-led opportunities.
- Experience as a Controls Engineer or in a related technical discipline.
Halma is a global holding company focused on safety, health, and environmental technologies. It builds a diversified portfolio by acquiring firms with strong intellectual property and growth potential, totaling over 200 acquisitions since 1972, with active businesses in sensors, safety, and medical technology. How it works: Halma's subsidiaries develop and sell products and systems that detect hazards, monitor health, and protect people and environments. These include sensor-based devices and safety technologies, often integrated into industrial, medical, and consumer applications. The company relies on the expertise and IP of its acquired businesses rather than one single product line, operating through a network of specialized units rather than a centralized product.”
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Milton Keynes, United Kingdom
Founded
1894
Get referred to Halma
See people who can refer or advise you
Simplify's Take
What believers are saying
- FY2026 revenue rose 15% to £2.58 billion, with EBIT up 22%.
- On 2 September 2026, Halma bought Pyxis, adding $39 million annual revenue in water monitoring.
- Dreampath and Pyxis expand recurring consumables and regulation-driven demand in healthcare and water.
What critics are saying
- Halma's single photonics customer reached 20% of group sales in FY2026.
- If hyperscaler spending slows in 2027, photonics growth and valuation compress immediately.
- Constance Baroudel left in 2026; any succession misstep at Marc Ronchetti's team hits execution.
What makes Halma unique
- Halma's 2026 portfolio spans safety, diagnostics, and environmental monitoring, all acquisition-led.
- Photonics gives Halma proprietary sensing advantages across data centers, lasers, and water analytics.
- Halma's standalone-acquisition model keeps Dreampath and Pyxis management, preserving local operator expertise.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Remote Work Options
Health Insurance
Dental Insurance
Vision Insurance
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Phone/Internet Stipend
Home Office Stipend
401(k) Retirement Plan
401(k) Company Match
Remote Work Options
Company News
Halma stock gains as Berenberg highlights photonics momentum. Published on 09/04/2026 at 22:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Halma stock edges higher after investors digest fresh analyst commentary on its photonics exposure and updated market data for the London listed safety technology group. The Halma stock (ISIN GB0004052071) closed at 3,604.00 pence on the London Stock Exchange on September 4, 2026, up 0.33% over the day according to market data compiled by MarketScreener. This modest move comes as investors focus on the group's positioning in photonics and environmental monitoring following new analyst commentary published on September 4, 2026. Analyst view supports Halma's valuation. According to an assessment relayed by MarketScreener on September 4, 2026, the average price target for Halma stands at 4,372.00 pence, implying upside of about 21.3% from the latest closing level of 3,604.00 pence. The same data snapshot indicates that Halma shares are up 1.87% year to date, while showing a five day performance of plus 0.33% as of September 4, 2026. The positive stance is tied in particular to Halma's exposure to photonics, where the bank notes strong momentum across applications such as sensing, imaging and laser based technologies. For equity investors, this means the valuation case increasingly depends on whether Halma can convert that photonics demand into sustained revenue and profit growth in its most recent financial periods. Deal activity and revenue expectations. A German language report on September 4, 2026 highlights that Halma expects unaudited revenue of about 39 million US dollars from a recently announced acquisition in the water quality segment for the twelve months to March 31, 2027. The same report notes that the Halma share gained around 0.3% in London trading on September 4, 2026 in reaction to the deal, broadly in line with the 0.33% move indicated by MarketScreener data. From an investor perspective, the 39 million US dollars revenue expectation for the acquired business over the period ending March 31, 2027 offers a concrete benchmark against which to judge execution. If Halma manages to integrate the company efficiently and achieve that run rate, the transaction could provide a meaningful contribution to the group's overall top line in its next fiscal year. Further details on Halma as an investment. For more background on Halma stock and its recent corporate communications, investors can consult the thematic overview and dedicated investor relations resources. Safety and environmental technologies as core business. Halma plc is a United Kingdom based safety technology group that focuses on products and services aimed at protecting life and improving environmental quality. Its portfolio spans sectors such as industrial safety, medical devices, environmental monitoring and analytical technologies, with photonics increasingly central to how its sensors and instruments capture and process data. Photonics, in this context, refers to technologies that use light for measurement and communication, including lasers, optical sensors and imaging systems. By embedding photonics into products such as gas detectors, water quality analyzers and medical imaging components, Halma can offer higher precision and reliability, which in turn supports pricing power and helps defend margins across its operating segments. Halma stock level and investor angle. As of the London close on September 4, 2026, Halma stock at 3,604.00 pence remains below the average analyst target of 4,372.00 pence compiled by MarketScreener, leaving a double digit percentage gap that many market participants will watch closely. The modest 0.33% daily gain suggests that the latest deal and analyst commentary have been digested calmly, without triggering a sharp rerating in the share price. Halma stock key data. * Company: Halma plc * ISIN: GB0004052071 * Ticker: HLMA * Trading venue: London Stock Exchange * Price (as of September 4, 2026, 17:35): 3,604.00 pence * Sector / Industry: Safety equipment and technology * Index membership: FTSE 100 Sponsored Ad Halma stock: new analysis - 5 September. Fresh Halma information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | GB0004052071 | HALMA | boerse | 70056532 | bgmi
Halma, a FTSE 100 life-saving technology company, has acquired Pyxis, a water quality monitoring specialist based near Houston, Texas. The deal comprises an initial $170 million cash payment, funded through existing credit facilities, plus potential earn-out payments of up to $30 million based on performance through March 2029. Pyxis, founded in 2013, develops sensors and connected monitoring systems for industrial, municipal, and environmental water applications. Its unaudited revenue forecast for the year ending March 2027 is approximately $39 million. The acquisition strengthens Halma's Environmental & Analysis Sector. Pyxis will operate as a standalone business under founder Caibin Xiao and its current management team. The deal is driven by increasing global water quality regulations. Halma has completed acquisitions of Pyxis' US and Chinese entities, with the European entity closure expected shortly.
FTSE 100 movers: Shell gushes higher after update; miners in the red. London's FTSE 100 was up 0.4% at 10,694.03 in afternoon trade on Tuesday. Drinks maker Diageo and consumer goods giant Unilever were among the top gainers. Shell also gushed higher as the oil giant said trading & optimisation earnings in its integrated gas division are expected to be "significantly" higher in the second quarter as it lifted its production guidance for the segment. The company expects Q2 production of 610,000 to 650,000 barrels of oil equivalent per day in its integrated gas arm, down from 909,000 boed in the first quarter due to the impact of the Middle East conflict on Qatari volumes. However, this was above its previous forecast for production of 580,000 to 640,000 boed in Q2. Shell also said it expects an improvement in its working capital position due to the impact of "unprecedented volatility" in commodity prices. It now expects a cash inflow of $1bn to $6bn in the second quarter, following a $11.2bn outflow in the first quarter. Heavily-weighted miners Anglo American and Antofagasta were under the cosh, along with precious metals miner Fresnillo, as gold prices fell. Halma retreated after announcing the acquisition of France-based Dreampath Diagnostics for an initial €154m (£132m), on a cash- and debt-free basis. FTSE 100 - Risers FTSE 100 - Fallers
Halma (LSE:HLMA) has entered into an agreement to acquire Strasbourg-based Dreampath Diagnostics, a specialist in automated solutions for tracking, storing and managing patient tissue samples used in anatomical pathology laboratories. Dreampath has developed a closed-platform system that combines hardware, software and recurring consumables to streamline complex laboratory workflows.
Halma has agreed to acquire Dreampath Diagnostics, a French provider of automated sample-tracking systems for pathology labs, for an initial €154 million. The deal includes a potential earn-out of up to €121 million based on performance through March 2028. Strasbourg-based Dreampath specialises in helping labs store, track and manage patient tissue samples throughout diagnostics. Its closed-loop system combines hardware, software and consumables, generating recurring revenue. The company is expected to post €33 million in revenue for the 12 months ending March 2027. The acquisition expands Halma's healthcare portfolio, adding capabilities in tissue sample management. Dreampath will operate as a standalone business, keeping its current management team. Group chief executive Marc Ronchetti said the deal positions Halma in a growing diagnostics market driven by aging populations and rising chronic disease rates.